Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment

Author(s): Gilberta Giacchetti, Federica Turchi, Marco Boscaro, Vanessa Ronconi.

Journal Name: Current Vascular Pharmacology

Volume 7 , Issue 2 , 2009

Submit Manuscript
Submit Proposal

Abstract:

Primary aldosteronism is the most common cause of secondary hypertension, accounting for about 10% of all forms of high blood pressure. Life-time pharmacological therapy is the treatment of choice for primary aldosteronism due to idiopathic adrenal hyperplasia (IHA), while adrenalectomy is effective in curing most patients with an aldosterone producing adenoma (APA). Far from being a benign form of hypertension, primary aldosteronism is characterized by the development of cardiovascular renal and metabolic complications, including left ventricular hypertrophy, myocardial infarction, atrial fibrillation and stroke, microalbuminuria, renal cysts as well as metabolic syndrome, glucose impairment and diabetes mellitus. We review recent clinical experience with the above mentioned complications and long-term outcomes of blood pressure normalization and cardiac, renal and gluco-metabolic complications in patients with primary aldosteronism, after medical treatment with mineralocorticoid receptor antagonists and surgical treatment. We conclude that removal of adrenal adenoma results in normalization of the renin-angiotensin-aldosterone system (RAAS) and of kalaemia and improvement of blood pressure levels in all patients. Complete resolution of hypertension is achieved in nearly half of treated patients. Moreover, unilateral adrenalectomy is the best treatment to have the regression of cardiovascular, renal and metabolic complications in patients with APA. On the other hand, targeted medical treatment with aldosterone antagonists improves blood pressure control and appears able to prevent the progression of cardiac and metabolic complications in patients with IHA.

Keywords: Primary aldosteronism, medical treatment, adrenalectomy, complications, mineralocorticoid receptor blockers

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 7
ISSUE: 2
Year: 2009
Page: [244 - 249]
Pages: 6
DOI: 10.2174/157016109787455716
Price: $58

Article Metrics

PDF: 8